PL424773A1 - Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów - Google Patents

Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów

Info

Publication number
PL424773A1
PL424773A1 PL424773A PL42477318A PL424773A1 PL 424773 A1 PL424773 A1 PL 424773A1 PL 424773 A PL424773 A PL 424773A PL 42477318 A PL42477318 A PL 42477318A PL 424773 A1 PL424773 A1 PL 424773A1
Authority
PL
Poland
Prior art keywords
cancer
leukemia
polysaccharide
thyroid
treatment
Prior art date
Application number
PL424773A
Other languages
English (en)
Inventor
Iga WASIAK
Tomasz CIACH
Aleksandra KULIKOWSKA-DARŁAK
Piotr Pietrzak
Agnieszka Sobiecka
Wioletta KOŚNIK
Joanna PIETRAS
Paweł ŻERO
Paweł Żuk
Justyna MAŁKOWSKA
Kinga ADAMSKA
Mikołaj CHROMIŃSKI
Adam Kiciak
Original Assignee
Nanovelos Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanovelos Spółka Akcyjna filed Critical Nanovelos Spółka Akcyjna
Priority to PL424773A priority Critical patent/PL424773A1/pl
Priority to CN201980017745.XA priority patent/CN112165933B/zh
Priority to KR1020207027492A priority patent/KR20200128694A/ko
Priority to EP19724635.8A priority patent/EP3761955A1/en
Priority to US16/978,476 priority patent/US20210052616A1/en
Priority to PCT/PL2019/050014 priority patent/WO2019172790A1/en
Publication of PL424773A1 publication Critical patent/PL424773A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworu, charakteryzuje się tym, że antracyklina jest wybrana z epirubicyny, daunorubicyny, doksorubicyny, idarubicyny, i przy czym nowotwór jest wybrany z guzów litych wieku dziecięcego, guza Wilmsa, mięsaków, mięsaka tkanek miękkich, mięsaka Ewinga, chłoniaków, chłoniaka nieziarniczego, białaczki, ostrej białaczki, białaczki limfoblastycznej, białaczki mieloblastycznej, białaczki szpikowej, szpiczaka mnogiego, choroby Hodgkina, nowotworu piersi, raka piersi, nowotworu płuc, raka płuc, drobnokomórkowego raka płuca, nowotworu żołądka, raka żołądka, nowotworu pęcherza moczowego, brodawczakowego raka pęcherza moczowego z komórek nabłonka przejściowego, nowotworu tarczycy, raka tarczycy, raka brodawkowatego lub pęcherzykowego tarczycy, nowotworu trzustki, raka szyjki macicy, raka jajnika, raka endometrium, nowotworu nerki, kostniakomięsaka, neuroblastomy, nowotworu jelita grubego.
PL424773A 2018-03-06 2018-03-06 Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów PL424773A1 (pl)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL424773A PL424773A1 (pl) 2018-03-06 2018-03-06 Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów
CN201980017745.XA CN112165933B (zh) 2018-03-06 2019-03-05 用于治疗肿瘤的多糖包裹蒽环霉素
KR1020207027492A KR20200128694A (ko) 2018-03-06 2019-03-05 종양의 치료에 사용하기 위한 다당류로 캡슐화된 안트라사이클린
EP19724635.8A EP3761955A1 (en) 2018-03-06 2019-03-05 Anthracycline encapsulated with polysaccharide for use in the treatment of tumours
US16/978,476 US20210052616A1 (en) 2018-03-06 2019-03-05 Anthracycline encapsulated with a polysaccharide for use in the treatment of tumours
PCT/PL2019/050014 WO2019172790A1 (en) 2018-03-06 2019-03-05 Anthracycline encapsulated with polysaccharide for use in the treatment of tumours

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL424773A PL424773A1 (pl) 2018-03-06 2018-03-06 Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów

Publications (1)

Publication Number Publication Date
PL424773A1 true PL424773A1 (pl) 2019-09-09

Family

ID=66554462

Family Applications (1)

Application Number Title Priority Date Filing Date
PL424773A PL424773A1 (pl) 2018-03-06 2018-03-06 Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów

Country Status (6)

Country Link
US (1) US20210052616A1 (pl)
EP (1) EP3761955A1 (pl)
KR (1) KR20200128694A (pl)
CN (1) CN112165933B (pl)
PL (1) PL424773A1 (pl)
WO (1) WO2019172790A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102300362B1 (ko) * 2019-10-08 2021-09-08 고려대학교 산학협력단 간세포성 암종 특이적 항암 치료진단제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130455A2 (en) * 2005-05-27 2006-12-07 Royer Biomedical, Inc. Bioresorbable polymer matrices and methods of making and using the same
EP1917004A2 (de) * 2005-08-19 2008-05-07 Magforce Nanotechnologies AG Verfahren zur einschleusung von therapeutischen substanzen in zellen
PL221351B1 (pl) * 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2550261B2 (ja) * 1992-05-20 1996-11-06 株式会社ディ・ディ・エス研究所 酸化カルボキシメチルマンノグルカンードキソルビシン複合体
EP2229147A2 (en) * 2007-12-03 2010-09-22 The Johns Hopkins University Methods of synthesis and use of chemospheres
CN101653612A (zh) * 2009-07-23 2010-02-24 复旦大学 利用白蛋白-葡聚糖制备的阿霉素纳米制剂及其应用
ES2982794T3 (es) * 2010-08-31 2024-10-17 Inserm Institut National De La Santeet De La Rech Medicale Microesferas de polisacáridos reticulados y sus usos biomédicos
CN104523598B (zh) * 2014-12-16 2017-11-14 中国科学院长春应用化学研究所 葡聚糖/阿霉素键合药纳米粒及其制备方法
KR101842059B1 (ko) * 2016-02-05 2018-03-26 인하대학교 산학협력단 음이온성 작용기 및 아크릴레이트기가 도입된 광가교성 덱스트란 고분자 약물전달체 및 이의 제조방법
CN105727309B (zh) * 2016-03-31 2019-04-30 中国药科大学 双敏感两亲性多糖-阿霉素偶联物及其药学组合物的制备和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130455A2 (en) * 2005-05-27 2006-12-07 Royer Biomedical, Inc. Bioresorbable polymer matrices and methods of making and using the same
EP1917004A2 (de) * 2005-08-19 2008-05-07 Magforce Nanotechnologies AG Verfahren zur einschleusung von therapeutischen substanzen in zellen
PL221351B1 (pl) * 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAVITA BISHT, AMARNATH MAITRA, DEXTRAN - DOXORUBICIN/CHITOSAN NANOPARTICLES FOR SOLID TUMOR THERAPY, 2009 *

Also Published As

Publication number Publication date
CN112165933B (zh) 2024-04-16
WO2019172790A1 (en) 2019-09-12
US20210052616A1 (en) 2021-02-25
KR20200128694A (ko) 2020-11-16
EP3761955A1 (en) 2021-01-13
CN112165933A (zh) 2021-01-01

Similar Documents

Publication Publication Date Title
Thrumurthy et al. Does surgery have a role in managing incurable gastric cancer?
Rao et al. Cutaneous angiosarcoma as a delayed complication of radiation therapy for carcinoma of the breast
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
AR061911A1 (es) Anticuerpo antagonista para el tratamiento del cancer
MA32140B1 (fr) Utilisation d'un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens
ES2571235T3 (es) Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
PE20230373A1 (es) Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo
RU2013128934A (ru) Наночастицы, несущие химиотерапевтическое противораковое лекарственное средство
PL424773A1 (pl) Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
Zanaboni et al. Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: results of a phase II multicentric study
CO5370684A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular
MX2020011823A (es) Metodos para tratar cancer con combinacion de anticuerpo anti-muerte programada-1 (pd-1) y conjugado de anticuerpo anti-factor de tejido y farmaco.
Narayan et al. Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer
Tsuda et al. Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer
Iqbal et al. Neoadjuvant chemotherapy in locally advanced breast cancer
Öven Ustaalioğlu et al. Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer
Ahmad et al. Frequency of primary solid malignant neoplasms in both sexes, as seen in our practice
Ţarcă et al. Borderline ovarian cyst treated by laparoscopic surgery
CA3156022A1 (en) METHODS OF TREATING CANCER USING A COMBINATION OF A PLATINUM AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
EA200600931A1 (ru) Антитело против igf-i-рецептора
Koh et al. Beware mis‐representation of PRODIGE 7: danger of throwing out the cytoreductive surgery baby with the hyperthermic intraperitoneal chemotherapy bathwater.
Kalkan et al. Cutaneous metastasis from transitional cell carcinoma of urinary bladder
Prakash et al. A Very Large Malignant Phyllodes Tumor with Skin Ulceration and Nipple Areola Complex Involvement—Still a Reality!!!
Elshennawy et al. Aberrant Activation of the Hedgehog Signaling Pathway in High Grade Serous Ovarian Cancer: A Potential Prognostic Marker